Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).

Ogawa K, Morito H, Hasegawa A, Daikoku N, Miyagawa F, Okazaki A, Fukumoto T, Kobayashi N, Kasai T, Watanabe H, Sueki H, Iijima M, Tohyama M, Hashimoto K, Asada H.

J Dermatol Sci. 2013 Jan;69(1):38-43. doi: 10.1016/j.jdermsci.2012.10.002. Epub 2012 Oct 26.

PMID:
23141052
2.

Differential diagnosis of severe cutaneous drug eruptions.

Bachot N, Roujeau JC.

Am J Clin Dermatol. 2003;4(8):561-72. Review.

PMID:
12862499
3.

Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases.

Saeki H, Tamaki K.

J Dermatol Sci. 2006 Aug;43(2):75-84. Epub 2006 Jul 21. Review.

PMID:
16859899
4.

Pharmacogenetics of cutaneous adverse drug reactions.

Aihara M.

J Dermatol. 2011 Mar;38(3):246-54. doi: 10.1111/j.1346-8138.2010.01196.x. Review.

PMID:
21342226
5.

Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS.

Darlenski R, Kazandjieva J, Tsankov N.

Clin Dermatol. 2015 Sep-Oct;33(5):538-41. doi: 10.1016/j.clindermatol.2015.05.005. Epub 2015 May 27. Review.

PMID:
26321400
6.

Phenotype standardization for immune-mediated drug-induced skin injury.

Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E, La Grenade L, Carleton B, Papaluca-Amati M, Demoly P, Shear NH.

Clin Pharmacol Ther. 2011 Jun;89(6):896-901. doi: 10.1038/clpt.2011.79. Epub 2011 May 11. Review.

PMID:
21562486
7.

Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Pavlos R, Mallal S, Ostrov D, Pompeu Y, Phillips E.

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):21-33. doi: 10.1016/j.jaip.2013.11.005. Review.

8.

Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review.

Ganeva M, Gancheva T, Lazarova R, Troeva J, Baldaranov I, Vassilev I, Hristakieva E, Tzaneva V.

Int J Dermatol. 2008 Aug;47(8):853-60. doi: 10.1111/j.1365-4632.2008.03637.x. Review.

PMID:
18717872
9.

The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug.

Kano Y, Shiohara T.

Immunol Allergy Clin North Am. 2009 Aug;29(3):481-501. doi: 10.1016/j.iac.2009.04.007. Review.

PMID:
19563993
10.

Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking.

Walsh SA, Creamer D.

Clin Exp Dermatol. 2011 Jan;36(1):6-11. doi: 10.1111/j.1365-2230.2010.03967.x. Review.

PMID:
21143513
11.

The DRESS syndrome: a literature review.

Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC.

Am J Med. 2011 Jul;124(7):588-97. doi: 10.1016/j.amjmed.2011.01.017. Epub 2011 May 17. Review.

PMID:
21592453
12.

[Drug-induced skin reactions].

Lammintausta K, Alanko K.

Duodecim. 2011;127(5):448-56. Review. Finnish.

PMID:
21491751
13.

Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update.

Tas S, Simonart T.

Dermatology. 2003;206(4):353-6. Review.

PMID:
12771485
14.

Drug rash with eosinophilia and systemic symptoms (DRESS syndrome).

Tas S, Simonart T.

Acta Clin Belg. 1999 Aug;54(4):197-200. Review.

PMID:
10544509
15.

Adverse cutaneous drug eruptions: current understanding.

Hoetzenecker W, Nägeli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, Guenova E, Cozzio A, French LE.

Semin Immunopathol. 2016 Jan;38(1):75-86. doi: 10.1007/s00281-015-0540-2. Epub 2015 Nov 9. Review.

PMID:
26553194
16.

Monitoring the acute response in severe hypersensitivity reactions to drugs.

Shiohara T, Mizukawa Y, Aoyama Y.

Curr Opin Allergy Clin Immunol. 2015 Aug;15(4):294-9. doi: 10.1097/ACI.0000000000000180. Review.

PMID:
26110678
17.

Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome.

Fernando SL.

Australas J Dermatol. 2014 Feb;55(1):15-23. doi: 10.1111/ajd.12085. Epub 2013 Jul 19. Review.

PMID:
23866082
18.

Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis.

Kataoka Y.

J Dermatol. 2014 Mar;41(3):221-9. doi: 10.1111/1346-8138.12440. Review.

PMID:
24628072
19.

HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.

Cheng CY, Su SC, Chen CH, Chen WL, Deng ST, Chung WH.

J Immunol Res. 2014;2014:565320. doi: 10.1155/2014/565320. Epub 2014 May 8. Review.

20.

Epidemiology of severe drug hypersensitivity.

Dodiuk-Gad RP, Laws PM, Shear NH.

Semin Cutan Med Surg. 2014 Mar;33(1):2-9. Review.

PMID:
25037253

Supplemental Content

Support Center